Bevacizumab (BEV), a humanized monoclonal antibody inhibiting VEGFA, was considered a promising candidate for treating GBM, given its clinical benefits in other cancers such as colorectal cancer [4], renal cell carcinoma [5], non-squamous non-small cell lung cancer [6], and cervical cancer [7]. The gene discussed is VEGFA; the disease is glioblastoma.